Where does Viridian Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$360.59M-17.0%	-$342.6M-26.9%	-$301.97M-17.5%	-$344.06M-50.9%	-$308.32M-41.3%
Depreciation and amortization	$464K-9.4%	$460K-14.8%	$463K-18.3%	$483K-15.6%	$512K-8.9%
Stock-based compensation	$47.47M+19.6%	$44.3M+5.1%	$41.29M-30.3%	$38.76M-39.5%	$39.68M-38.6%
Change in accounts payable	——	——	$4.02M+72.2%	$5.4M+867%	$1.21M+125%
Change in accrued liabilities	——	——	——	——	$6.33M—
Change in other assets	——	——	-$2.44M—	$4.84M—	——
Other working capital changes	-$332K+45.9%	-$157K+74.7%	$69.38M+9,425%	-$518K+38.8%	-$614K+17.6%
Net cash from operating activities	-$303.39M-8.5%	-$276.39M-19.0%	-$325.97M-65.5%	-$309.06M-83.7%	-$279.75M-67.1%
Capital expenditures	$432K-27.6%	$495K-3.1%	$369K-17.1%	$535K-3.8%	$597K-23.8%
Purchases of investments	$599.35M+10.8%	$579.28M-16.7%	$322.86M-58.9%	$537.2M-11.6%	$540.7M-2.8%
Proceeds from maturities/sales of investments	$539.42M-2.9%	$542.21M+16.1%	$562.17M+24.7%	$565.93M+39.7%	$555.76M+66.9%
Net cash from investing activities	-$60.36M—	-$37.56M—	$238.94M—	$28.2M—	——
Proceeds from issuance of common stock	$60.09M—	$65.03M—	$50.43M—	——	——
Payment of debt issuance costs	——	$478K—	$358.5K+179%	$239K-7.0%	$119.5K-69.0%
Net cash from financing activities	$423.89M+46.2%	$426.74M-6.8%	$56.36M-90.9%	$290.52M-25.8%	$289.87M-26.5%
Net increase (decrease) in cash	$60.13M+145%	$112.79M+3,589%	-$30.67M-135%	$9.66M—	$24.57M—
Interest paid	$2.82M+55.3%	$2.15M+18.1%	$1.82M-0.2%	$1.82M+15.6%	$1.82M+48.1%
Accretion (Amortization) of Discounts and Premiums, Investments	$6.3M-52.7%	$6.76M-56.8%	$8.21M-47.1%	$10.46M-28.8%	$13.31M+1.0%
Derivative Gain Loss On Derivative Net	——	——	——	——	$0—
Issuance costs allocated to derivative liability	——	$1.75M—	$1.31M—	$875.5K—	$437.75K—
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	-$2.44M—	$4.84M—	——
Other Noncash Income (Expense)	——	——	——	——	-$614K+17.6%
Payment-in-kind interest	——	——	——	——	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$539.42M-2.9%	$542.21M+16.1%	$562.17M+24.7%	$565.93M+39.7%	$555.76M+66.9%
Payment Of Issuance Costs, Sale Of Future Revenue	——	$4.98M—	$3.74M—	$2.49M—	$1.25M—
Payments Of Debt Issuance Costs	——	$478K—	$358.5K+179%	$239K-7.0%	$119.5K-69.0%
Payments Of Stock Issuance Costs	——	——	——	——	——
Proceeds from issuances of debt	——	$55M—	$41.25M—	$27.5M—	$13.75M—
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——	$879K—
Proceeds From Issuance Of Warrants	——	——	——	——	$1.62M—
Remeasurement of right-of-use asset and lease liability for lease modifications	——	$0-100%	$209.25K-73.4%	$418.5K-43.4%	$627.75K-9.0%
Free cash flow	-$303.82M-8.4%	-$276.89M-18.9%	-$326.34M-65.3%	-$309.6M-83.4%	-$280.35M-66.7%
Free cash flow	-$303.82M-8.4%	-$276.89M-18.9%	-$326.34M-65.3%	-$309.6M-83.4%	-$280.35M-66.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Viridian Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.